<DOC>
	<DOCNO>NCT01191775</DOCNO>
	<brief_summary>This study sponsor Sierra Oncology , Inc. formerly ProNAi Therapeutics , Inc . The purpose research study evaluate safety investigational drug PNT2258 patient advance tumor see act body .</brief_summary>
	<brief_title>A Study PNT2258 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study open-label , single-arm , Phase 1 dose-escalation study PNT2258 patient advance solid tumor standard therapy exists . Patients receive PNT2258 intravenous infusion daily 5 consecutive day ( Days 1-5 ) every 21-day cycle ( 3 week ) . At first , patient treat single patient cohort follow accelerated titration design evaluate toxicity . After accelerated portion end , patient treat cohort least 3 patient dose level evaluate treatment-related toxicity .</detailed_description>
	<criteria>Histologically confirm , malignant solid tumor ( measurable nonmeasurable disease ) candidate know regimen protocol treatment higher efficacy priority . Recovered Grade 1 acute toxicity prior therapy , except residual toxicity , alopecia , pose ongoing medical risk . ECOG performance status 0 , 1 , 2 . At least 18 year age . Patients must normal organ marrow function define : Absolute neutrophil count 1,500/µL Platelets 100,000/µL Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) 2.5 x institutional upper limit normal ( ULN ) 5.0 x ULN patient liver metastasis Serum creatinine 1.5 x ULN measure creatinine clearance 60 mL/min/1.73 m2 . Negative serum pregnancy test time enrollment woman childbearing potential . For men woman childproducing potential , use effective contraceptive method require study . Ability understand requirement study . Must provide write informed consent authorization use disclosure protect health information . Must agree abide study restriction return required assessment . Received previous anticancer chemotherapy , immunotherapy , radiotherapy investigational therapy 4 week ( 6 week nitrosoureas mitomycin C ) prior study entry . Receiving investigational agent . Known brain metastasis exception patient history treat brain metastasis stable least 3 month glucocorticoid seizure medication . Prolongation QT/QTc interval &gt; 450 millisecond ( m ) . Known HIV , HBV , HCV infection . History allergic reaction attribute compound similar chemical biologic composition PNT2258 . History allergic reaction egg chicken antigen . Pregnant nursing woman . Uncontrolled intercurrent illness include , limited ongoing serious active infection , symptomatic congestive heart failure , unstable angina pectoris , serious cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oligonucleotide</keyword>
	<keyword>DNAi</keyword>
	<keyword>Oncology</keyword>
	<keyword>Antineoplastic agent</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>PNT2258</keyword>
</DOC>